Biotech

Incanthera has broken a clinical barrier in skincare. Its range is about to enter the real world. Incanthera (AQSE: INC) shares are currently changing hands for 15p apiece, more than doubling since the start of the year. This is a growth stock which has been on my radar for a while, ever since the market […]

From cystic fibrosis to diabetes to strep — every medical find requires refinement and improvement over time. There is a video floating around out there, of an ex Royal Marine being treated for previously untreatable Parkinson’s Disease. I also quite like the ones of deaf people getting cochlear implants switched on for the first time. […]

Avacta retains a significant set of oncology assets. But this, by itself, is not enough to be successful in the biotech space. Before we get started, I want to make clear that this is not an article designed to rub salt in the wound. If you are feeling betrayed, hurt, financially violated, or otherwise — […]

Avacta, Hemogenyx, Cizzle and Poolbeg Pharma remain my top four biotech picks for 2024. Here’s why. There are many, many biotechs out there. Most are funding trials into a single flagship treatment — with a standard Chance of Success of circa 10%. However, when research houses talk about a 10% CoS, this concerns scientific success […]

HEMO’s investment case is much strengthened since January, though the immediate cash issues remain a concern. my thoughts below. Hemogenyx. It’s been a while since I covered this oncology portfolio stock — last running through the investment case in late January 2023. I’d encourage would-be investors who are new to the company to briefly scan […]

Oxford Biodynamics shares have shot up, and deservedly so. However, there will likely be a pullback for a better entry point. Oxford Biodynamics (LON: OBD) shares were changing hands for as much as 278p five years ago and had collapsed to circa 10.5p towards the end of September 2023. The share has now shot up […]

Cizzle shares now look decent value for long-term investors — a strong component for the biotech portfolio. Read the condensed update below. With a slew of AIM companies reporting results — I thought it would be a good idea to take a brief look at Cizzle for the first time since late February. Alongside Avacta […]

Key things you need to know about investing in small cap oncology research stocks — including the best biotech on the AIM market. As a freelance financial analyst, I spend most of my time evaluating EIS-qualifying companies for high net worth investors, alongside coverage of market titans for blue chip clients. Much of this material […]

As with every article featured here, none of this is investing or financial advice. We encourage you to conduct your own research. Here at Investing Strategy, we like to cover high-risk, high-reward shares in select sectors which provide the best opportunities in relatively short time frames. One of these sectors is biotechs (or life sciences) […]

ABDX is shortly launching a world-first saliva pregnancy test. It could become the global standard. Abingdon Health (LON: ABDX) shares have shot up by over 100% year-to-date as investors in the FTSE AIM biotech are finally starting to see some light at the end of the tunnel. The company put to bed a hotly contested […]